OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis
Renuka Suvarna, Sahana Shetty, Joseph M. Pappachan
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Renuka Suvarna, Sahana Shetty, Joseph M. Pappachan
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Showing 6 citing articles:
Resmetirom and thyroid hormone receptor‐targeted treatment for metabolic dysfunction‐associated steatotic liver disease (MASLD)
Chang‐Hai Liu, Qingchun Zeng, Tianxiao Hu, et al.
Portal hypertension & cirrhosis (2025)
Open Access
Chang‐Hai Liu, Qingchun Zeng, Tianxiao Hu, et al.
Portal hypertension & cirrhosis (2025)
Open Access
Metabolic Dysfunction-Associated Steatotic Liver Disease: An Overview of Pharmacotherapy
Mohamed Toufic El Hussein, Daniel Favell
The Journal for Nurse Practitioners (2025) Vol. 21, Iss. 2, pp. 105273-105273
Closed Access
Mohamed Toufic El Hussein, Daniel Favell
The Journal for Nurse Practitioners (2025) Vol. 21, Iss. 2, pp. 105273-105273
Closed Access
Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review
Stavros Topouzis, Andreas Papapetropoulos, S P H Alexander, et al.
British Journal of Pharmacology (2025)
Open Access
Stavros Topouzis, Andreas Papapetropoulos, S P H Alexander, et al.
British Journal of Pharmacology (2025)
Open Access
Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom
Elizabeta Knezović, Marija Hefer, Suzana Blažanović, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 3, pp. 154-154
Open Access
Elizabeta Knezović, Marija Hefer, Suzana Blažanović, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 3, pp. 154-154
Open Access
Roles of extracellular vesicles from different origins in metabolic-associated fatty liver disease: progress and perspectives
Xinyi Wang, Sônia Nair Báo, Qi An, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Xinyi Wang, Sônia Nair Báo, Qi An, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Prevalence of Metabolic‐Associated Steatotic Liver Disease in Patients With Primary Aldosteronism
Irene Tizianel, Alberto Madinelli, Filippo Crimì, et al.
Clinical Endocrinology (2025)
Open Access
Irene Tizianel, Alberto Madinelli, Filippo Crimì, et al.
Clinical Endocrinology (2025)
Open Access
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis
Sheena Bhushan, Aalam Sohal, Mazen Noureddin, et al.
Expert Opinion on Pharmacotherapy (2025)
Closed Access
Sheena Bhushan, Aalam Sohal, Mazen Noureddin, et al.
Expert Opinion on Pharmacotherapy (2025)
Closed Access
Hepatic thyroid hormone receptor‐β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction‐associated steatohepatitis
Stergios A. Pοlyzos, Giovanni Targher
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 1
Stergios A. Pοlyzos, Giovanni Targher
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 1
